Risk Factors Update Summary
- The net loss increased from $372 million in 2022 to $152 million in 2023.
- Accumulated deficit increased from approximately $400 million to $403 million in 2023.
- The number of granted patents worldwide increased from approximately 35 to 56.
- The closing price of common stock ranged from $23 to $44 in January 2023 to 2024.
- The potential commercial launch of arthroscopically delivered MACI is anticipated in 2024.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=887359&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.